RAC Regulatory Strategic Planning 3 — Questions and Answers
Question 1: Which tool is most useful for proactively identifying regulatory risks before a product submission?
- SWOT analysis applied to regulatory activities
- FMEA (Failure Mode and Effects Analysis) of the regulatory strategy (Correct answer)
- A Gantt chart of submission milestones
- Post-market surveillance data review
Correct answer: FMEA (Failure Mode and Effects Analysis) of the regulatory strategy
FMEA applied to regulatory strategy systematically identifies potential failure modes in the regulatory plan and their impact on approval timelines.
Question 2: A company seeks approval in both the EU and US simultaneously. The primary benefit of using the ICH CTD format is:
- It eliminates the need for separate clinical trials in each region
- It provides a harmonized submission structure accepted by both FDA and EMA (Correct answer)
- It guarantees simultaneous approval timelines
- It removes the requirement for region-specific labeling
Correct answer: It provides a harmonized submission structure accepted by both FDA and EMA
The ICH CTD (Common Technical Document) provides a standardized format accepted by FDA, EMA, and other ICH member agencies, reducing duplication in preparing dossiers.
Question 3: When should a regulatory strategy be formally reassessed during product development?
- Only at NDA/BLA submission
- At predefined decision points and when significant new data emerge (Correct answer)
- Annually regardless of development milestones
- Only when FDA issues a complete response letter
Correct answer: At predefined decision points and when significant new data emerge
Regulatory strategy should be reassessed at defined decision gates (e.g., end-of-Phase 2) and whenever significant new clinical, safety, or competitive data emerge.
Question 4: Which FDA program is specifically designed to expedite development and review of drugs for serious conditions where preliminary evidence shows advantage over available therapy?
- Accelerated Approval
- Fast Track Designation (Correct answer)
- Priority Review
- Breakthrough Therapy Designation
Correct answer: Fast Track Designation
Fast Track Designation is designed to facilitate development and expedite review of drugs for serious conditions that demonstrate potential to address unmet medical needs.
Question 5: In EU regulatory strategy, the primary purpose of a Scientific Advice procedure with EMA is:
- To obtain binding commitments on approval timelines
- To gain EMA guidance on data requirements before a marketing authorization application (Correct answer)
- To replace the CHMP review process for urgent products
- To negotiate pricing and reimbursement terms
Correct answer: To gain EMA guidance on data requirements before a marketing authorization application
EMA Scientific Advice provides non-binding guidance on the data package and study designs needed to support a future marketing authorization application.
Question 6: A biosimilar regulatory strategy differs from a standard biologic strategy primarily because it requires:
- A full de novo clinical development program identical to the reference product
- A totality-of-evidence approach demonstrating no clinically meaningful differences from the reference product (Correct answer)
- Orphan drug designation to qualify for abbreviated pathways
- Only analytical characterization with no clinical data
Correct answer: A totality-of-evidence approach demonstrating no clinically meaningful differences from the reference product
Biosimilar approval relies on a totality-of-evidence approach showing no clinically meaningful differences from the reference product in terms of safety, purity, and potency.
Question 7: The concept of 'regulatory intelligence' in strategic planning involves:
- Monitoring competitor regulatory filings and agency guidance to inform strategy (Correct answer)
- Conducting espionage on regulatory agency internal deliberations
- Reviewing only published FDA guidance documents quarterly
- Tracking adverse event reports in public databases
Correct answer: Monitoring competitor regulatory filings and agency guidance to inform strategy
Regulatory intelligence involves systematically monitoring regulatory agency activities, competitor filings, guidance documents, and industry trends to inform and update regulatory strategy.
RAC Regulatory Strategic Planning 3
Which tool is most useful for proactively identifying regulatory risks before a product submission?